Vertex backs out of agreement with CRISPR Therapeutics for stem cell therapy candidate in diabetes
Vertex Pharmaceuticals’ subsidiary ViaCyte is backing out of one of its collaborations with CRISPR Therapeutics on gene-edited stem cell therapies for diabetes.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.